4'-tert-butoxycarbonylamino-2'-methyl-biphenyl-3-sulfinic acid methyl ester | 911030-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-tert-butoxycarbonylamino-2'-methyl-biphenyl-3-sulfinic acid methyl ester
• 英文别名: methyl 3-[2-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzenesulfinate
• CAS: 911030-57-4
• 化学式: C₁₉H₂₃NO₄S
• 分子量: 361.462
• InChiKey: ZZIFYVOKYRWVGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  83.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4'-tert-butoxycarbonylamino-2'-methyl-biphenyl-3-sulfinic acid methyl ester 在 copper(II) bis(trifluoromethanesulfonate) 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 2.58h， 生成 4-[S-[3-(4-carbamic acid tert-butyl ester-6-methyl-phenyl)phenyl]-N-3-nitro-phenylsulfoximino]-5-chloro-thiophene-2-carbonitrile
  参考文献：
  名称：

  WO2006/101860

  摘要：

  公开号：
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 5.0h， 以77%的产率得到4'-tert-butoxycarbonylamino-2'-methyl-biphenyl-3-sulfinic acid methyl ester
  参考文献：
  名称：

  WO2006/101860

  摘要：

  公开号：

文献信息

• Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions
  申请人：Subasinghe L. Nalin

  公开号：US20070066667A1

  公开（公告）日：2007-03-22

  Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R a , R b , and R c are defined in the specification, as are A Z, Q, R 1 and R 2 .

  本发明涉及一种用于治疗由补体级联经典途径介导的急性或慢性疾病症状的化合物。所述化合物为I式的化合物或其溶剂化物、水合物、药学上可接受的盐或前药；其中Ra、Rb和Rc在规范中定义，A、Z、Q、R1和R2也在规范中定义。
• NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS
  申请人：Subasinghe Nalin L.

  公开号：US20080255108A1

  公开（公告）日：2008-10-16

  Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R a , R b , and R c are defined in the specification, as are A Z, Q, R 1 and R 2 .

  本发明涉及用于治疗由补体级联的经典途径介导的急性或慢性疾病症状的化合物。所述化合物为I式化合物或其溶剂化物、水合物、药学上可接受的盐或前药；其中Ra、Rb和Rc在说明书中定义，A、Z、Q、R1和R2也在说明书中定义。
• Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：Janssen Pharmaceutica N.V.

  公开号：US07385066B2

  公开（公告）日：2008-06-10

  Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specification, as are A Z, Q, R1 and R2.

  本发明涉及用于治疗经典途径介导的急性或慢性疾病症状的化合物。该化合物为I式或其溶剂化物、水合物、药学上可接受的盐或其前药；其中Ra、Rb和Rc在说明书中定义，以及A、Z、Q、R1和R2也在说明书中定义。
• NOVEL THIOPHENE SULFOXIMINES FOR TREATING CMPLEMENT-MEDIATED DESEASES AND CONDITIONS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1863785A1

  公开（公告）日：2007-12-12
• NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1863785B1

  公开（公告）日：2009-12-02